STOCK TITAN

Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announced that Bobak Azamian, M.D., Ph.D., CEO and Chairman, will participate in a fireside chat at the 2024 Bank of America Healthcare Conference. The event aims to revolutionize treatment for patients, starting with eye care. The webcast and presentation details are available on the Tarsus website.

Positive
  • None.
Negative
  • None.

IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, will participate in an in-person fireside chat at the 2024 Bank of America Healthcare Conference taking place in Las Vegas, NV, on Wednesday, May 15, at 1:55 p.m. PT / 4:55 p.m. ET.

A live webcast and additional information about the presentation can be accessed on the events section of the Tarsus website. The replay will be available on the Tarsus website within 48 hours and will be archived for a limited time.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-03 as an investigational therapy for the treatment of Meibomian Gland Disease, TP-04 for the treatment of rosacea and TP-05 as an oral tablet for the prevention of Lyme disease, all of which are in Phase 2.

Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
akemp@tarsusrx.com

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com


FAQ

When will Bobak Azamian participate in the fireside chat at the 2024 Bank of America Healthcare Conference?

Bobak Azamian will participate on Wednesday, May 15, at 1:55 p.m. PT / 4:55 p.m. ET.

Where will the Bank of America Healthcare Conference take place?

The conference will be in Las Vegas, NV.

Where can additional information about the presentation be accessed?

Additional information can be found on the events section of the Tarsus website.

Will there be a replay of the presentation available?

Yes, the replay will be available on the Tarsus website within 48 hours and will be archived for a time.

Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

TARS Rankings

TARS Latest News

TARS Stock Data

1.44B
24.39M
4.26%
90.03%
20.93%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
IRVINE

About TARS

tarsus pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. its lead product candidate is tp-03, a novel therapeutic that is in phase iib/iii for the treatment of blepharitis caused by the infestation of demodex mites, as well as to treat meibomian gland disease. the company is also developing tp-04 for the treatment of rosacea; and tp-05 for lyme prophylaxis and community malaria reduction. tarsus pharmaceuticals, inc. was founded in 2016 and is headquartered in irvine, california.